Usage of human lysozyme in preparation of dermics

A technology of human lysozyme and skin diseases, which is applied in the pharmaceutical field of human lysozyme to achieve good medicinal prospects, simple preparation process and convenient use

Inactive Publication Date: 2005-03-16
张华
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Staphylococcus aureus (MRSA) has no cure except vancomycin, and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0235] The recombinant human lysozyme with a purity of 85%-99% is prepared from 300U to 3 million U / mL, phosphate buffer 10-20mM (pH6.5-7.5) 80%, 5-25% propylene glycol, 5 / 10000 Tween 80, mixed homogeneously at room temperature, (in a pharmaceutical factory that meets the requirements of GMP, according to pharmaceutical regulations) to make a spray.

Embodiment 2

[0237] The recombinant human lysozyme with a purity of 85%-99% is prepared, 300U~3 million / ml, phosphate buffer 10 (pH6.0) 80%, 5~20% propylene glycol, 6% 2-pyrrolidone-5- Sodium carboxylate, 0.9% water-soluble azone, 3 / 10,000 Tween 80 (in a pharmaceutical factory meeting the GMP requirements, completed according to pharmaceutical regulations) drops, milk, emulsion.

Embodiment 3

[0239] Made from 85%-99% recombinant human lysozyme, 300U-3 million U / ml / g, phosphate buffer 20mM (pH7.0) 85%, 5-20% propylene glycol, 3 / 10,000 Tween 80 , Carboresin 1%, essence 0.3% (in a pharmaceutical factory meeting GMP requirements, according to pharmaceutical regulations) cream.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of human lysozyme in pharmaceutical industry, in particular the use in preparing medicines for treating dermatosis, infection and ulceration caused by bacteria, fungus, viruses, allergic reaction, and occupational diseases, physical diseases, nerve dysfunctional diseases, and immunity diseases. The invention exploits the novel use of human lysozyme in medical treatment, the gene recombination lysozyme has rich source, the invention also features simple process for manufacturing, and ease in use.

Description

Technical field: [0001] The present invention relates to the application of human lysozyme, especially the new application of human lysozyme in the pharmaceutical field. Background technique: [0002] Skin diseases are caused by a variety of factors, and the occurrence and development of these diseases are related to factors such as internal and external factors of the body, the response status of the host, heredity and personal qualities. Skin diseases are sometimes mild and easily overlooked, and sometimes they can involve internal organs. If they are not diagnosed and treated early, they can lead to serious consequences. Many skin diseases are caused by bacteria, and antibiotics have a good effect. Antibiotics have created many medical miracles and made many diseases disappear without a trace, such as pneumonia, meningitis, puerperal fever, sepsis, tuberculosis, etc. But today in the 21st century, the external use of antibiotics has led to the emergence of a large numbe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K9/06A61K9/107A61K9/12A61K38/48A61P17/00A61P17/02A61P17/04A61P17/06
Inventor 张华
Owner 张华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap